Detection of Hypoxia With 18F-Fluoromisonidazole (18F-FMISO) PET/CT in Suspected or Proven Pancreatic Cancer

Segard, Tatiana; Robins, Peter; Yusoff, Ian F.; Ee, Hooi; Morandeau, Laurence; Campbell, Elaine M.; Francis, Roslyn J.

doi:10.1097/rlu.0b013e3182708777

Cited by 50 publications

(31 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In contrast, our results showed more clustered areas of hypoxia, with good repeatability. Compared to an earlier in vivo study where [ 18 F]FMISO hypoxia imaging was performed in pancreatic cancer, we observed higher image contrast and were better able to visually identify areas with increased tracer uptake [48]. This could well be explained by the longer time between injection and scanning (2 h vs. 3.5 h) and the faster background clearance of [ 18 F]HX4 compared to [ 18 F]FMISO [38].…”

Section: Discussioncontrasting

confidence: 40%

Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer

Klaassen

Bennink

Tienhoven

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

Section: Discussioncontrasting

confidence: 40%

Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer

Klaassen

Bennink

Tienhoven

et al. 2015

Radiotherapy and Oncology

View full text Add to dashboard Cite

show abstract

“…Koh et al [221] , Liu et al [222] , Yeh et al [223] , Rischin et al [224] , Bentzen et al [125] , Rajendran et al [225] , Gagel et al [126] , Rajendran et al [226] , Hicks et al [227] , Lawrentschuk et al [200] , Loi et al [228] , Thorwarth et al [229] , Rajendran et al [230] , Rischin et al [231] , Thorwarth et al [232] , Zimny et al [124] , Eschmann et al [233] , Gagel et al [202] , Thorwarth et al [234] , Thorwarth et al [235] , Lee et al [236] , Lin et al [237] , Nehmeh et al [238] , Roels et al [239] , Dirix et al [240] , Lee et al [241] , Mortensen et al [127] , Wang et al [56] , Abolmaali et al [242] , Bowen et al [138] , Eary et al [243] , Kikuchi et al [244] , Hugonnet et al [131] , Yamane et al [245] , Mammar et al [246] , Zips et al [247] , Cheng et al [217] , Henriques de Figueiredo et al [248] , Okamoto et al [249] , Sato et al [218] , Segard et al [250] , Tachibana et al [251] , Norikane et al [219] [ Dubois et al …”

Section: F]fmisomentioning

confidence: 99%

Positron emission tomography to assess hypoxia and perfusion in lung cancer

Verwer

Boellaard

Veldt

2014

WJCO

View full text Add to dashboard Cite

Core tip:This review provides an overview of the current applications of positron emission tomography for hypoxia and perfusion imaging in lung cancer. Available PET tracers are discussed and the benefits of combined hypoxia and perfusion PET imaging are clarified. Hypoxia imaging could aid in selecting patients for hypoxia-specific treatment strategies. To achieve this, consensus about the optimal imaging protocol and quantification method is essential. Large clinical trials are needed to confirm the value of hypoxia imaging for improving patient care.Verwer EE, Boellaard R, van der Veldt AAM. Positron emission tomography to assess hypoxia and perfusion in lung cancer.

show abstract

“…4,5). Two prominent characteristics of pancreatic cancer, hypoperfusion and desmoplasia, play important roles in forming the hypoxic microenvironment (6).…”

Section: Introductionmentioning

confidence: 99%

HIF-3α Promotes Metastatic Phenotypes in Pancreatic Cancer by Transcriptional Regulation of the RhoC–ROCK1 Signaling Pathway

Zhou

Guo

Chen

et al. 2018

Molecular Cancer Research

View full text Add to dashboard Cite

Hypoxia contributes to pancreatic cancer progression and promotes its growth and invasion. Previous research principally focused on hypoxia-inducible factor-1 alpha (HIF-1a) and HIF2a (HIF1A and EPAS1) as the major hypoxia-associated transcription factors in pancreatic cancer. However, the role of HIF-3a (HIF3A) has not been investigated. Therefore, HIF-1a, HIF-2a, and HIF-3a expression levels were measured under normoxic and hypoxic conditions. In addition, HIF-3a expression was measured in human pancreatic cancer tissue specimens and the impact of altered HIF-3a expression on cell invasion and migration was investigated in vitro and in vivo, as well as the underlying mechanisms. Under hypoxic conditions, HIF-3a expression was stimulated in pancreatic cancer cells to a greater degree than HIF-1a and HIF-2a expression. HIF-3a protein levels were also elevated in pancreatic cancer tissues and correlated with reduced survival and greater local invasion and distant metastasis, whereas knockdown of HIF-3a, under hypoxic conditions, suppressed pancreatic cancer cell invasion and migration. Under normoxia, HIF-3a overexpression promoted pancreatic cancer cell invasion and migration and stimulated F-actin polymerization. In summary, HIF-3a promotes pancreatic cancer cell invasion and metastasis in vivo and promotes pancreatic cancer cell invasion and metastasis by transcriptionally activating the RhoC-ROCK1 signaling pathway.Implications: HIF3a is overexpressed in pancreatic cancer, and targeting the HIF3a/RhoC-ROCK1 signaling pathway may be a novel therapeutic approach for the treatment of pancreatic cancer invasion and metastasis.

show abstract

Detection of Hypoxia With 18F-Fluoromisonidazole (18F-FMISO) PET/CT in Suspected or Proven Pancreatic Cancer

Cited by 50 publications

References 22 publications

Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer

Feasibility and repeatability of PET with the hypoxia tracer [18F]HX4 in oesophageal and pancreatic cancer

Positron emission tomography to assess hypoxia and perfusion in lung cancer

HIF-3α Promotes Metastatic Phenotypes in Pancreatic Cancer by Transcriptional Regulation of the RhoC–ROCK1 Signaling Pathway

Contact Info

Product

Resources

About